Bluebird bio Inc (BLUE): Street Finally Waking Up

Currently, there are 192.74M common shares owned by the public and among those 189.83M shares have been available to trade.

However, the script later moved the day high at 1.2500, down -2.42%. The company’s stock has a 5-day price change of -11.03% and -12.32% over the past three months. BLUE shares are trading -12.32% year to date (YTD), with the 12-month market performance down to -61.46% lower. It has a 12-month low price of $0.88 and touched a high of $5.53 over the same period. BLUE has an average intraday trading volume of 9.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.67%, -2.97%, and -54.72% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Bluebird bio Inc (NASDAQ: BLUE) shares accounts for 67.25% of the company’s 192.74M shares outstanding.

It has a market capitalization of $233.22M and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.37% over the week and 10.83% over the month.

Analysts forecast that Bluebird bio Inc (BLUE) will achieve an EPS of -$0.66 for the current quarter, -$0.47 for the next quarter and -$1.66 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.98 while analysts give the company a high EPS estimate of -$0.45. Comparatively, EPS for the current quarter was $0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 10.66%, and 45.82% over the next financial year. EPS should grow at an annualized rate of 45.80% over the next five years, compared to 15.14% over the past 5-year period.

Morgan Stanley coverage for the Bluebird bio Inc (BLUE) stock in a research note released on December 08, 2023 offered a Equal-Weight rating with a price target of $7. Cantor Fitzgerald was of a view on October 17, 2023 that the stock is Neutral, while HSBC Securities gave the stock Buy rating on September 06, 2023, issuing a price target of $4.21. BofA Securities on their part issued Buy rating on July 19, 2023.

Most Popular

Related Posts